PSMA-ALB-56

PSMA-ALB-56 is a PSMA-targeting radioligand designed by combining the glutamate-urea PSMA-binding entity and an albumin binder[1].

Product Specifications

CAS Number

[2306049-48-7]

UNSPSC

12352203

Target

Drug-Linker Conjugates for ADC

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/psma-alb-56.html

Purity

99.04

Solubility

10 mM in DMSO

Smiles

O=C([C@H]1CC[C@@H](CC1)CNC([C@H](CCCCNC(CCCC2=CC=C(C=C2)C)=O)NC(CN3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)N[C@H](C(NCCCC[C@@H](C(O)=O)NC(N[C@H](C(O)=O)CCC(O)=O)=O)=O)CC4=CC5=C(C=CC=C5)C=C4

Molecular Formula

C66H95N11O18

Molecular Weight

1330.52

References & Citations

[1]Umbricht CA, et al. Preclinical Development of Novel PSMA-Targeting Radioligands: Modulation of Albumin-Binding Properties To Improve Prostate Cancer Therapy. Mol Pharm. 2018;15 (6) :2297-2306.